收藏切换
Preparation and in vitro-in vivo Evaluation of Elagolix Sodium Tablets
收藏切换
Junwei JIA1, 2, Zhixiang ZHU1, Zhengzhao LI1, Yujiang PANG1, Liping ZHANG2, Zhong FENG1, 2, *
Chinese Journal of Pharmaceuticals | 2024, 55(2) : 253 - 260
Less
收藏切换
Chinese Journal of Pharmaceuticals | 2024, 55(2): 253-260
• Paper •
Preparation and in vitro-in vivo Evaluation of Elagolix Sodium Tablets
Full
Junwei JIA1, 2, Zhixiang ZHU1, Zhengzhao LI1, Yujiang PANG1, Liping ZHANG2, Zhong FENG1, 2, *
Affiliations
  • 1.Ocean University of China, Qingdao 266003
  • 2.Pharmaceutical Internationalization Engineering Lab. of Shandong Province, Lunan Pharmaceutical Group Co., Ltd., Linyi 273400
Published: 2024-02-10 doi: 10.16522/j.cnki.cjph.2024.02.012
Outline
收藏切换

In this study, elagolix sodium self-developed tablets were formulated by optimizing three key formulation process parameters, namely the particle size of active pharmaceutical ingredient(API), the aperture of sieve screen in the dry granulation process, and the tablet hardness. The similarity factor (f2) values between the dissolution curves of the self-developed and reference tablets were calculated as a criterion for evaluation. The results indicated that when the API particle size[d(0.9)] was 250 μm, the aperture of sieve screen was 1.4 mm, and the tablet hardness was 80 N, the in vitro dissolution behavior of the self-developed tablets was similar to that of the reference formulations. Subsequently, bioequivalence was investigated using relevant permeation parameters from the parallel artificial membrane permeation assay(PAMPA) and pharmacokinetic characteristics in Beagle dogs. The results revealed that the permeation rates of the self-developed tablets and the reference formulations were 8.698 8 and 8.161 6 μg·mL–1·min–1 respectively, with membrane permeabilities of 2.24×10–4 and 2.10×10–4 cm/s. The confidence interval for the self-developed tablets ranged from 100.82% to 104.54%. There was no statistically significant difference in the pharmacokinetic parameters between the two groups(P>0.05). The relative bioavailability of the self-developed tablets was found to be (95.4±8.69)%, demonstrating the bioequivalence with the reference formulations.

elagolix sodium  /  process parameter  /  parallel artificial membrane permeability assay  /  bioequivalence
贾俊伟, 朱志祥, 李正照, 庞余江, 张丽萍, 冯中. 𫫇拉戈利钠片的制备及体内外评价. 中国医药工业杂志, 2024 , 55 (2) : 253 -260 . DOI: 10.16522/j.cnki.cjph.2024.02.012
Junwei JIA, Zhixiang ZHU, Zhengzhao LI, Yujiang PANG, Liping ZHANG, Zhong FENG. Preparation and in vitro-in vivo Evaluation of Elagolix Sodium Tablets[J]. Chinese Journal of Pharmaceuticals, 2024 , 55 (2) : 253 -260 . DOI: 10.16522/j.cnki.cjph.2024.02.012
Year 2024 volume 55 Issue 2
17
3
Cite this Article
BibTeX
Article Info
doi: 10.16522/j.cnki.cjph.2024.02.012
  • Receive Date:2023-05-24
  • Online Date:2026-11-19
  • Published:2024-02-10
Article Data
Affiliations
History
  • Received:2023-05-24
Affiliations
    1.Ocean University of China, Qingdao 266003
    2.Pharmaceutical Internationalization Engineering Lab. of Shandong Province, Lunan Pharmaceutical Group Co., Ltd., Linyi 273400
References
Share
https://castjournals.cast.org.cn/joweb/zgyygy/EN/10.16522/j.cnki.cjph.2024.02.012
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT